Core Viewpoint - Vanda Pharmaceuticals calls for stronger FDA action to accelerate the transition from animal testing to human-relevant methods in drug development, expressing concerns over the FDA's draft guidance released on March 18, 2026 [1][2]. Summary by Sections FDA Draft Guidance - The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs) to modernize nonclinical testing and reduce reliance on traditional animal models [2]. - Vanda acknowledges the FDA's commitment to improving human predictivity and ethical standards but believes the draft lacks the necessary reforms for effective implementation [2]. Vanda's Advocacy - Vanda has a history of advocating for science-driven changes, including legal challenges against prolonged animal studies that lack scientific justification [3]. - The company emphasizes the ethical need to minimize animal suffering while advancing predictive human-relevant methods [3]. Key Shortcomings in the Draft - The draft guidance is criticized for vague validation requirements, insufficient transparency, and a lack of concrete examples of accepted NAMs [5]. - There are no specific NAMs mentioned that the FDA currently accepts to replace required animal tests, which creates uncertainty for developers [5]. Recommendations for FDA - Vanda urges the FDA to collaborate with industry innovators and animal welfare groups to refine the guidance [5]. - The company calls for clear pathways for regulatory acceptance that prioritize human relevance and evidence-based confidence [5]. - Vanda suggests incorporating robust citations and specific examples of validated NAMs to enhance the guidance [5][6].

Vanda Pharmaceuticals Conference Call Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovation to enhance people's happiness. The company has five approved products in the U.S. including: - **Fanapt**: An atypical antipsychotic for bipolar disorder and schizophrenia - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome - **Ponvory**: Approved for multiple sclerosis - **NEREUS**: Recently approved for motion sickness - **Bysanti**: Approved for bipolar disorder and schizophrenia [2][3] Financial Position - Vanda ended the previous year with over **$260 million** in cash and no debt, indicating a strong financial position [3] - Revenue from Fanapt was **$117 million** in 2025, up from just under **$100 million** in 2024, with forecasts for **$150 million to $170 million** in 2026 [13][14] Product Pipeline and Growth Strategy - Vanda aims to grow and diversify revenue through existing products and new approvals, targeting **six approved products** by the end of the year [4] - Upcoming regulatory catalysts include: - **Imsidolimab**: BLA accepted for review with a PDUFA date of **December 12, 2026** [4] - **Bysanti**: Phase 3 study in major depressive disorder (MDD) with results expected by the end of 2026 [7][9] Bysanti's Market Potential - Bysanti's approval is expected to extend the revenue runway for Vanda's psychiatry portfolio, with potential label expansion for MDD [13][14] - The market size for schizophrenia and bipolar disorder is estimated at **10 million** patients, while MDD is approximately **20 million**, indicating significant growth potential [22] - Bysanti's pricing structure is expected to be more favorable than Fanapt, potentially leading to higher revenue [15][16] Commercialization Strategy - Vanda plans to leverage its existing psychiatry sales force for the launch of Bysanti in Q3 2026 [17][19] - The company anticipates that Bysanti could surpass Fanapt in demand due to its growth trajectory and market potential [20] NEREUS and Motion Sickness Market - NEREUS targets a market of **70 million** people in the U.S. experiencing motion sickness, with over **10 million** seeking treatment [51] - The product is expected to command premium pricing due to its favorable side effect profile compared to existing treatments [52] - Launch is anticipated in **mid-2026** [57] Research and Development Milestones - Vanda is focused on advancing its late-stage pipeline, including: - Phase 3 programs for NEREUS in GLP-1 market and Bysanti in MDD - Phase 3 for Fanapt long-acting injectable in schizophrenia [48] Regulatory Challenges - Vanda faced a Complete Response Letter (CRL) for NEREUS in gastroparesis but is pursuing a hearing with the FDA to present its case [78][80] - The company is optimistic about the potential for a favorable outcome based on recent legal victories [78] Future Outlook - Vanda's revenue guidance for 2026 is set at **$230 million to $260 million**, with specific targets for Fanapt, Ponvory, and Hetlioz [40][41] - The company is in an investment phase, expecting higher cash burn in 2026 due to product launches and pipeline investments [47] Conclusion - Vanda Pharmaceuticals is positioned for growth with a strong product pipeline and strategic focus on expanding its market presence in psychiatry and motion sickness. The company is navigating regulatory challenges while preparing for significant product launches in the near future.

Core Insights - The FDA has granted Vanda Pharmaceuticals a formal evidentiary public hearing regarding the proposed refusal of the supplemental new drug application (sNDA) for HETLIOZ® in treating jet lag disorder, marking the first such hearing in over 40 years [1] - This decision reflects Vanda's persistence over seven years in advocating for the approval of HETLIOZ® and highlights a significant reform step by the FDA towards greater transparency [1] - The hearing follows a favorable ruling from the U.S. Court of Appeals for the D.C. Circuit, which criticized the FDA for not adequately engaging with Vanda's evidence and remanded the matter for resolution [1] Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing innovative therapies to address unmet medical needs [1] - HETLIOZ® (tasimelteon) is currently approved for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome, with the pending sNDA seeking to expand its approval to jet lag disorder [1] Market Context - Jet lag disorder affects millions of travelers globally, including business travelers, athletes, and military personnel, and currently lacks an FDA-approved therapeutic option [1]

Core Viewpoint - Vanda Pharmaceuticals Inc. will participate in the 2026 Citizens Life Sciences Conference, highlighting its commitment to addressing unmet medical needs through innovative therapies [1] Group 1: Conference Participation - The conference is scheduled for March 11, 2026, in Miami, with a corporate presentation at 2:15 p.m. Eastern Time [1] - Investors can access the live presentation on Vanda's corporate website and are advised to register at least 15 minutes early [1] - An archived version of the conference will be available on Vanda's website for approximately 30 days post-event [1] Group 2: Company Overview - Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on developing and commercializing innovative therapies [1] - The company aims to address high unmet medical needs and improve patient lives [1]

Group 1 - B. Riley raised the price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 while maintaining a Buy rating on the shares [1] - The revenue model for Vanda has been updated following the approval of BYSANTI, reflecting expected growth in the psychiatry franchise [1] - Peak sales for BYSANTI are now included in the revenue model, with probability adjustments removed [1] Group 2 - Base assumptions include mid-to-high single-digit quarter-over-quarter growth in BYSANTI/FANAPT prescriptions through 2026 [1]

Core Insights - Vanda Pharmaceuticals' shares rose following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, indicating potential market capture in these areas [1] - The FDA accepted Vanda's Biologics License Application for imsidolimab for Generalized Pustular Psoriasis, with a target action date of December 12 [2] Group 1: Bysanti Approval - The FDA's approval of Bysanti is expected to establish it as a first-line therapy for acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults [5] - Bysanti is projected to be commercially available in Q3 2026, with marketing exclusivity lasting until 2044 [5] - Clinical studies showed Bysanti demonstrated bioequivalence to iloperidone, leveraging established efficacy and safety data from Vanda's previous drug, Fanapt, which had net product sales of $33.2 million in Q4 2025, reflecting a 25% year-over-year increase [6] Group 2: Imsidolimab for GPP - GPP is characterized by sudden eruptions of sterile, pus-filled blisters on the skin and systemic symptoms like fever and fatigue [3] - In pivotal studies, a single intravenous dose of imsidolimab led to 53% of patients achieving clear or almost clear skin at Week 4 compared to 13% on placebo [3] - Efficacy was maintained over a two-year maintenance period with no flares in the active treatment group [4] Group 3: Market Performance and Technical Analysis - Vanda's stock was up 4.53% at $8.53 during the publication time, aligning with a generally favorable market backdrop where the S&P 500 rose by 0.34% and Nasdaq gained 0.42% [7][10] - Currently, Vanda is trading 5.5% below its 20-day simple moving average and 10.2% below its 100-day simple moving average, indicating short-term weakness [8] - The stock carries a Buy Rating with an average price target of $18.11, with recent analyst upgrades raising targets to $24.00 and $14.00 [10]

Core Viewpoint - Vanda Pharmaceuticals has announced the FDA's acceptance of the Biologics License Application for imsidolimab, targeting Generalized Pustular Psoriasis, with a decision expected by December 12, 2026 [1] Company Overview - Vanda Pharmaceuticals is focused on developing innovative therapies to meet high unmet medical needs, particularly in rare orphan diseases [1] - The company has a growing portfolio in anti-inflammatory treatments and rare orphan disorders [1] Product Details - Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling, aimed at treating Generalized Pustular Psoriasis (GPP) [1] - The drug has shown promising results in clinical studies, with 53% of patients achieving clear or almost clear skin at Week 4 compared to 13% on placebo [1] - Imsidolimab has a favorable safety profile, with a low incidence of anti-drug antibodies, which may provide an advantage over existing treatments [1] Market Potential - GPP is a rare and life-threatening disorder, with prevalence estimates ranging from approximately 2 to 124 cases per million worldwide [1] - If approved, imsidolimab will be Vanda's third new drug product approved in the past 12 months, following NEREUS™ and BYSANTI™ [1] Regulatory Milestone - The acceptance of the BLA filing for imsidolimab is celebrated during Rare Disease Week, highlighting the importance of innovation and access to treatments for rare diseases [1]

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights such as buy and sell ratings, product sales forecasts for major pharmaceutical companies, and detailed financial analyses [1]

Core Insights - Vanda Pharmaceuticals experienced a significant stock price increase of approximately 45% following the FDA's approval of its treatment for schizophrenia and bipolar I disorder [1] Company Summary - The FDA has granted approval for Vanda Pharmaceuticals' treatment, which is expected to enhance the company's market position in the psychiatric treatment sector [1]

Core Viewpoint - Vanda Pharmaceuticals' shares are experiencing an increase following the FDA's approval of Bysanti, a new treatment for bipolar I disorder and schizophrenia, marking a significant milestone for the company [1][2]. FDA Approval - The FDA has approved Bysanti as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults [2]. - Bysanti is classified as a new chemical entity (NCE) and belongs to the atypical antipsychotics category [2]. Clinical Studies - In clinical studies, Bysanti showed bioequivalence to iloperidone across the therapeutic dosing spectrum, leveraging established efficacy and safety knowledge from the clinical development program and over 100,000 patient-years of real-world experience with Fanapt (iloperidone) [3]. - Fanapt's net product sales reached $33.2 million in Q4 2025, reflecting a year-over-year increase of 25% [3]. Commercial Roadmap - Bysanti is expected to be commercially available in Q3 2026, with marketing exclusivity protected by regulatory data exclusivity and US patents expiring in 2044 [4]. - Bysanti is also being tested as a once-daily adjunctive treatment for treatment-resistant major depressive disorder, with ongoing clinical studies expected to conclude by the end of this year [4]. Technical Analysis - The stock is currently trading 5.5% below its 20-day simple moving average (SMA) and 10.2% below its 100-day SMA, indicating short-term weakness [5]. - Over the past 12 months, shares have increased by 25%, and they are closer to their 52-week highs than lows, suggesting strong long-term performance [5]. - The RSI is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [5][6]. Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $18.10 [7]. - Recent analyst actions include: - HC Wainwright & Co. raised the target to $22.00 with a Buy rating [7]. - B. Riley Securities raised the target to $14.00 with a Buy rating [7]. - Jefferies raised the target to $7.50 with a Hold rating [7]. - Vanda Pharmaceuticals shares were up 35.59% at $7.81 during premarket trading [7].